Munich – the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics conference is one of my favourite meetings on the cancer circuit. It’s small enough that you can catch people in the corridor and have a quick chat, while at the same time large enough that it attracts quality data. It’s also the place where you find people who think outside the box.

I want to hear from thought leaders who have the potential to be disrupters.

feuerwurstTalking of another kind of disruption, sadly the travel chaos caused by the Lufthansa pilot’s strike(s) meant some people didn’t make it to the meeting or arrived late. Despite the best efforts of Lufthansa, there was still a good turnout of posters today and several caught my attention!

Those who follow our cancer conference coverage know that the poster hall is often where the gems and insights are to be found, particularly when it comes to early drug development.

If you couldn’t make it to Munich, this post has commentary on four gems from the Wednesday poster session at EORTC-NCI-AACR that caught my attention. I’ve chosen to focus on novel targets and novel combination approaches…

Subscribers can login to read more or you can purchase access below

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTs & WRITERs), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.